DaVita Inc. (NYSE:DVA) Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP increased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 61.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,147 shares of the company's stock after buying an additional 10,753 shares during the period. Quantinno Capital Management LP's holdings in DaVita were worth $4,209,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in DaVita during the 4th quarter valued at $41,000. Coppell Advisory Solutions LLC boosted its position in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. Canada Post Corp Registered Pension Plan purchased a new position in DaVita in the fourth quarter valued at about $55,000. Venturi Wealth Management LLC raised its holdings in DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after purchasing an additional 152 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after buying an additional 131 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Performance

Shares of NYSE DVA traded down $2.30 during midday trading on Thursday, reaching $138.55. The company had a trading volume of 627,437 shares, compared to its average volume of 829,422. DaVita Inc. has a 1 year low of $131.44 and a 1 year high of $179.60. The business's 50-day simple moving average is $145.76 and its 200 day simple moving average is $153.46. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock has a market cap of $10.46 billion, a P/E ratio of 12.90, a P/E/G ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The company had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The firm's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $2.26 EPS. On average, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DVA shares. Truist Financial cut their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research report on Monday. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.